# Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer

> **NCT00122265** · — · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 83 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00122265
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2016-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122265, "Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00122265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*